Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207363 | 1.00 | CA12 (0.36) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL6207655 | 1.00 | CA12 (0.36) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL31099064 | 0.97 | CA12 (0.35) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL2962998 | 0.81 | CA14 (0.41) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL9784197 | 0.81 | DGAT1 (0.37) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL4248802 | 0.81 | DGAT1 (0.37) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL8773691 | 0.81 | DGAT1 (0.37) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL24123445 | 0.80 | CA12 (0.34) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL3210435 | 0.80 | CA1 (0.37) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL6534429 | 0.79 | NOS1 (0.38) | CA12CA14DGAT1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 921 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122037208-A | Polyfluorene-polystyrene-polyfluorene triblock copolymer with high solid state photoluminescence efficiency and synthesis method thereof | 常州工程职业技术学院 | 2026-05-15 | — | — | CN | claimed |
| CN-119859208-A | Binary free radical polymerization method | 上海交通大学 | 2025-04-22 | — | — | CN | claimed |
| CN-119351000-A | Low-viscosity easy-tearing protective film and preparation method thereof | 江阴市江泰高分子新材料有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-115959993-B | Synthesis method of 2-aryl propionic acid compound | 山东中医药大学 | 2025-01-07 | — | — | CN | claimed |
| CN-118772551-A | Polymer wax-like PVC decorative film and preparation method thereof | 杭州领科新材料有限公司 | 2024-10-15 | — | — | CN | claimed |
| CN-115028551-B | Preparation method of azide-nine glycol-propionic acid | 成都普康生物科技有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-117285590-A | Compound, preparation method thereof, composition comprising compound and application of compound | 中国人民解放军军事科学院军事医学研究院 | 2023-12-26 | — | — | CN | claimed |
| US-11773109-B2 | Composition for hardening soft tissue | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION | 2023-10-03 | — | — | US | claimed |
| CN-116515922-A | Method for promoting lignocellulose enzymolysis by utilizing cation-nonionic copolymer | 华南理工大学 | 2023-08-01 | — | — | CN | claimed |
| CN-116496505-A | Synthesis of polystyrene-polyfluorene copolymer luminescent material | 常州工程职业技术学院 | 2023-07-28 | — | — | CN | claimed |
| CN-115959993-A | Synthetic method of 2-aryl propionic acid compound | 山东中医药大学 | 2023-04-14 | — | — | CN | claimed |
| CN-115028551-A | Preparation method of azido-nonaethylene glycol-propionic acid | 成都普康生物科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-113651964-B | Lignin-based multifunctional composite flocculant and preparation method and application thereof | 华南理工大学 | 2022-05-24 | — | — | CN | claimed |
| CN-113651964-A | Lignin-based multifunctional composite flocculant and preparation method and application thereof | 华南理工大学 | 2021-11-16 | — | — | CN | claimed |
| CN-109280174-B | Hyperbranched lignin grafted cationic polyacrylamide flocculant and preparation method thereof | 华南理工大学 | 2020-09-22 | — | — | CN | claimed |
| CN-107880157-B | Preparation method and application of polyvinylpyrrolidone | 重庆斯泰克瑞登梅尔材料技术有限公司 | 2020-05-29 | — | — | CN | claimed |
| US-20150203639-A1 | POLYTHIOPHENE STAR COPOLYMER CAPABLE OF BEING SELF-DOPED BY EXTERNAL STIMULUS, A METHOD FOR PRODUCING THE SAME, A CONDUCTIVE THIN FILM USING THE SAME, AND A METHOD FOR PRODUCING THE CONDUCTIVE THIN FILM | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-07-23 | — | — | US | claimed |
| US-20030236407-A1 | Perfluoroalkyl group-containing micelle-forming triiodoaromatic compounds, process for their production and their use as contrast media | SCHERING AG (DE) | 2003-12-25 | — | — | US | claimed |
| WO-2003072560-A1 | TRIIODINE AROMATICS CONTAINING PERFLUOROALKYL GROUPS AND FORMING MICELLES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS CONTRAST MEDIA | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-09-04 | — | — | WO | claimed |
| CN-122037208-A | Polyfluorene-polystyrene-polyfluorene triblock copolymer with high solid state photoluminescence efficiency and synthesis method thereof | 常州工程职业技术学院 | 2026-05-15 | — | — | CN | disclosed |
| US-20260132121-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12624018-B1 | Inhibitors of RIPK2 and medical uses thereof | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12624028-B2 | 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | disclosed |
| US-20260109715-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2026-04-23 | — | — | US | disclosed |
| EP-4720036-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| US-12594339-B2 | Lipid prodrugs of JAK inhibitors and uses thereof | SEAPORT THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260091081-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| US-20260078209-A1 | SILICONE HYDROGEL INK BINDER FOR CONTACT LENSES | BAUSCH & LOMB IRELAND LTD (IE) | 2026-03-19 | — | — | US | disclosed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | disclosed |
| EP-4034535-B1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| US-12544374-B2 | AZA-quinoline compounds and uses thereof | NOVARTIS AG (CH) | 2026-02-10 | — | — | US | disclosed |
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12508321-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-12-30 | — | — | US | disclosed |
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| US-12496351-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-12478695-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-11-25 | — | — | US | disclosed |
| US-12472265-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| EP-4646240-A1 | BIOMEDICAL DEVICES HAVING A SURFACE COATING | Bausch + Lomb Ireland Limited (IE) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025215096-A1 | SILICONE CONTACT LENS-FORMING PREPOLYMER AND SILICONE CONTACT LENS FORMED THEREFROM | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-10-16 | — | — | WO | disclosed |
| US-12440466-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2025-10-14 | — | — | US | disclosed |
| US-12433950-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-10-07 | — | — | US | disclosed |
| EP-4622970-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-09-11 | — | — | US | disclosed |
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | SITRYX THERAPEUTICS LIMITED (GB) | 2025-08-19 | — | — | US | disclosed |
| EP-4600246-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | Public University Corporation Yokohama City University (JP) | 2025-08-13 | — | — | EP | disclosed |
| US-12364767-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-07-22 | — | — | US | disclosed |
| US-12358925-B2 | Targeted ubiquitination degradation BRD4 protein compound, preparation method therefor and application thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2025-07-15 | — | — | US | disclosed |
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2025137541-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-3962602-B1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2025-06-25 | — | — | EP | disclosed |
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4562015-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4562006-A1 | N-HETEROCYLIC GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-120040335-A | Indoxyl sulfate derivative, immunogen, antibody and detection reagent preparation and application | 胥江生物科技(苏州)有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-4556007-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | Shanghai Raising Pharmaceutical Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| US-12303571-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-05-20 | — | — | US | disclosed |
| EP-4551577-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025092827-A1 | EPOXY COMPOUND AND USE THEREOF | 上海汇伦医药股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096653-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096662-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096658-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096654-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096660-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096657-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119923395-A | N-heterocyclic GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods of use thereof | 卡莫特医疗有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-12285491-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-04-29 | — | — | US | disclosed |
| CN-119859208-A | Binary free radical polymerization method | 上海交通大学 | 2025-04-22 | — | — | CN | disclosed |
| CN-119790058-A | Fused cyclic KRAS inhibitors for the treatment of diseases | 荣山医药股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119775137-A | Preparation method of (S) -2- (2-fluoro- [1,1' -biphenyl ] -4-yl) propionic acid | 江苏中卫康医药研发有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119735532-A | Alpha-fluoro chalcone derivative and application thereof | 杭州百诚医药科技股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119638611-A | N-acetyl-5-hydroxytryptamine derivative, immunogen, antibody and detection reagent preparation and application | 胥江生物科技(苏州)有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119497615-A | TPK agonists and methods of using the same for treating neurodegenerative diseases | 上海日馨医药科技股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2025036290-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2025-02-20 | — | — | WO | disclosed |
| US-12221449-B2 | Pyrrolopyrimidine derivative and use thereof | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-02-11 | — | — | US | disclosed |
| US-12220464-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-02-11 | — | — | US | disclosed |
| EP-4499656-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034027-A1 | METHOD FOR PREPARING GLASS NANOSTRUCTURES AND NANOSTRUCTURED SUBSTRATES THEREOF | CORNING INCORPORATED | 2025-01-30 | — | — | US | disclosed |
| CN-119351000-A | Low-viscosity easy-tearing protective film and preparation method thereof | 江阴市江泰高分子新材料有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20250019380-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| CN-119301127-A | 6-Oxo-decahydro pyrrolo [1,2-a ] [1,5] diazocine and 6-oxo-decahydro-4H-pyrrolo [2,1-d ] [1,5] thiaazacine derivatives as modulators of STAT3 and STAT6 for the treatment of cancer and inflammatory conditions | 瑞克鲁迪克斯制药股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-115959993-B | Synthesis method of 2-aryl propionic acid compound | 山东中医药大学 | 2025-01-07 | — | — | CN | disclosed |
| US-20240425513-A1 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | CARMOT THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| CN-119183453-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| WO-2024255412-A1 | SPIRO HETEROCYCLIC COMPOUND AND USE THEREOF | 广州必贝特医药股份有限公司 | 2024-12-19 | — | — | WO | disclosed |
| WO-2024243692-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400587-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-12-05 | — | — | US | disclosed |
| CN-112824380-B | Alpha-fluoro chalcone derivative and application thereof | 杭州百诚医药科技股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20240391875-A1 | ISOQUINOLINONES AND QUINOLINONES AS MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-11-07 | — | — | US | disclosed |
| EP-3720431-B1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-10-30 | — | — | EP | disclosed |
| WO-2024217872-A1 | RIGID GAS PERMEABLE PREPOLYMER AND RIGID GAS PERMEABLE CONTACT LENS FORMED THEREFROM | BAUSCH + LOMB IRELAND LIMITED (IE) | 2024-10-24 | — | — | WO | disclosed |
| US-20240352170-A1 | RIGID GAS PERMEABLE PREPOLYMER AND RIGID GAS PERMEABLE CONTACT LENS FORMED THEREFROM | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-10-24 | — | — | US | disclosed |
| CN-118791471-A | Preparation method of besudil | 斯坦德药典标准物质研发(湖北)有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-114746414-B | Aza-quinoline compounds and uses thereof | 诺华公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118772551-A | Polymer wax-like PVC decorative film and preparation method thereof | 杭州领科新材料有限公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-4430052-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12091426-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | NURIX THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD (CN) | 2024-09-12 | — | — | US | disclosed |
| EP-3919498-B3 | PYRROLOPYRIMIDINE DERIVATIVE AND USE THEREOF | WUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY (CN) | 2024-09-04 | — | — | EP | disclosed |
| CN-113473987-B | Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same | 细胞基因公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024175086-A1 | ARYL TRICYCLIC STING AGONIST AND USE THEREOF | 深圳真实生物医药科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| EP-4419508-A2 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | Carmot Therapeutics, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12065443-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2024-08-20 | — | — | US | disclosed |
| US-12065541-B2 | Thermoplastic resin, optical film made therefrom, diol compound, diester compound | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-08-20 | — | — | US | disclosed |
| CN-115151256-B | Novel compounds for the treatment of diseases associated with DUX4 expression | 因维戈疗法有限公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2024158872-A1 | 1,3-INDOLE-PROPANAMIDE INHIBITORS OF SARS-COV-2 PLPRO/NSP3 AND DERIVATIVES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 2024-08-02 | — | — | WO | disclosed |
| US-20240245788-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2024-07-25 | — | — | US | disclosed |
| CN-118359600-A | Aryl imidazolyl isoxazole compound as well as preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2024-07-19 | — | — | CN | disclosed |
| US-20240240047-A1 | BIOMEDICAL DEVICES HAVING A SURFACE COATING | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-07-18 | — | — | US | disclosed |
| EP-4399210-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | Black Diamond Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024146878-A1 | BIOMEDICAL DEVICES HAVING A SURFACE COATING | BAUSCH + LOMB IRELAND LIMITED (IE) | 2024-07-11 | — | — | WO | disclosed |
| CN-118307400-A | Preparation method of S-flurbiprofen | 金仓(上海)医药生物科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118302414-A | Oxazole, oxadiazole and indole derivatives useful for inhibiting USP28 | 卡莫特医疗有限公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4392420-A1 | HPK1 DEGRADERS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-07-03 | — | — | EP | disclosed |
| EP-3919498-B1 | PYRROLOPYRIMIDINE DERIVATIVE AND USE THEREOF | WUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-113365699-B | Target ubiquitin degradation BRD4 protein compound, and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-115052596-B | ADAMTS inhibitor, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118159537-A | 6-Aza-quinoline derivatives and related uses | 黑钻治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| US-11998584-B2 | Conjugate of a tubulysin analog with branched linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-06-04 | — | — | US | disclosed |
| WO-2024112854-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-3253737-B3 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| CN-118063316-A | Preparation method of 3- (1- (tert-butoxy) -1-oxo-propyl-2-yl) benzoic acid | 无锡捷化医药科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4370124-A1 | PI3Ka INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240156769-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-05-16 | — | — | US | disclosed |
| CN-112543764-B | Amide compound with BET proteolytic induction effect and medical application thereof | 田边三菱制药株式会社 | 2024-05-10 | — | — | CN | disclosed |
| US-20240150364-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-11975073-B2 | Lipid prodrugs of neurosteroids | PURETECH LYT, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-11958802-B2 | Migration-resistant photopolymerization sensitizer | KAWASAKI KASEI CHEMICALS LTD. (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-117881683-A | PI3K alpha inhibitors and methods of use thereof | 传达治疗有限公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2024075696-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | 公立大学法人横浜市立大学 | 2024-04-11 | — | — | WO | disclosed |
| CN-117858874-A | HPK1 degrading agents, compositions comprising the same, and methods of use thereof | 百放开曼有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-111433200-B | Compounds and pharmaceutical compositions for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-113518779-B | Thieno heterocyclic derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11925614-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2024-03-12 | — | — | US | disclosed |
| WO-2024026481-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026338-A1 | N-HETEROCYLIC GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024012554-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | 上海日馨医药科技股份有限公司 | 2024-01-18 | — | — | WO | disclosed |
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-01-16 | — | — | US | disclosed |
| CN-115028551-B | Preparation method of azide-nine glycol-propionic acid | 成都普康生物科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-117285590-A | Compound, preparation method thereof, composition comprising compound and application of compound | 中国人民解放军军事科学院军事医学研究院 | 2023-12-26 | — | — | CN | disclosed |
| CN-113292539-B | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117186112-A | Universal fluorescent probe for selectively and sensitively detecting carbonyl halide | 遵义医科大学 | 2023-12-08 | — | — | CN | disclosed |
| US-11819531-B2 | Multifunctional zwitterionic polymer conjugates | KODIAK SCIENCES INC. (US) | 2023-11-21 | — | — | US | disclosed |
| CN-116969918-A | Fluoro substituted pyridone derivative and its pharmaceutical composition, preparation method and use | 上海美悦生物科技发展有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116693505-B | Compound for targeted degradation of EGFR protein and preparation method and application thereof | 中国药科大学 | 2023-10-27 | — | — | CN | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| CN-113825757-B | Substituted fused bicyclic derivatives, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-3988599-B1 | THERMOPLASTIC RESIN, OPTICAL FILM MADE THEREFROM, DIOL COMPOUND, DIESTER COMPOUND | MITSUBISHI CHEM CORP (JP) | 2023-10-18 | — | — | EP | disclosed |
| CN-116891502-A | EGFR degrading agent | 上海齐鲁制药研究中心有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-11779663-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| CN-113166036-B | Photopolymerizing sensitizers with migration resistance | 川崎化成工业株式会社 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023192960-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11773109-B2 | Composition for hardening soft tissue | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION | 2023-10-03 | — | — | US | disclosed |
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230277616-A9 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2023-09-07 | — | — | US | disclosed |
| CN-116693505-A | Compound for targeted degradation of EGFR protein and preparation method and application thereof | 中国药科大学 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023164680-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| WO-2023143374-A1 | LIGAND, METHOD FOR PREPARING SAME, AND USE THEREOF | 成都凌泰氪生物技术有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-116515922-A | Method for promoting lignocellulose enzymolysis by utilizing cation-nonionic copolymer | 华南理工大学 | 2023-08-01 | — | — | CN | disclosed |
| CN-116496505-A | Synthesis of polystyrene-polyfluorene copolymer luminescent material | 常州工程职业技术学院 | 2023-07-28 | — | — | CN | disclosed |
| US-11702430-B2 | Aza-benzothiophene compounds as STING agonists | MERCK SHARP & DOHME LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702430-B2 | Aza-benzothiophene compounds as STING agonists | MERCK SHARP & DOHME LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702430-B2 | Aza-benzothiophene compounds as STING agonists | MERCK SHARP & DOHME LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| EP-3018118-B1 | BASE GENERATOR, BASE-REACTIVE COMPOSITION CONTAINING SAID BASE GENERATOR, AND BASE GENERATION METHOD | FUJIFILM WAKO PURE CHEMICAL CORP (JP) | 2023-07-05 | — | — | EP | disclosed |
| US-20230165931-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165930-A1 | CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| CN-116143678-A | Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116157396-A | Pyridazinone derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2023086399-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230149502-A1 | CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20230136702-A1 | Inhibitors of Human Herpesviruses | THE GOVERNORS OF THE UNIVERSTIY OF ALBERTA (CA) | 2023-05-04 | — | — | US | disclosed |
| WO-2023069721-A2 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | CARMOT THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-115959993-A | Synthetic method of 2-aryl propionic acid compound | 山东中医药大学 | 2023-04-14 | — | — | CN | disclosed |
| CN-115322208-B | 2-aminothiazole derivative and preparation method and medical application thereof | 中国药科大学 | 2023-04-11 | — | — | CN | disclosed |
| CN-112574207-B | ERK1/2 protein kinase inhibitor and application thereof | 南京药石科技股份有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-110099682-B | Coupled connector, cell binding molecule-drug conjugate containing same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2023039505-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| US-20230083012-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2023-03-16 | — | — | US | disclosed |
| US-20230071112-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-03-09 | — | — | US | disclosed |
| WO-2023034344-A1 | ISOQUINOLINONES AND QUINOLINONES AS MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023025091-A1 | HPK1 DEGRADERS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | BIOFRONT LTD (CAYMAN) (KY) | 2023-03-02 | — | — | WO | disclosed |
| CN-115715292-A | 1H-pyrazolo [4,3-g ] isoquinoline and 1H-pyrazolo [4,3-g ] quinoline derivatives as alpha-1-antitrypsin modulators for the treatment of alpha-1-antitrypsin deficiency (AATD) | 弗特克斯药品有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-02-16 | — | — | US | disclosed |
| EP-4126863-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | Vertex Pharmaceuticals Incorporated (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4125914-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230025327-A1 | CONJUGATES OF TUBULYSIN DERIVATIVES AND CELL BINDING MOLECULES AND METHODS OF MAKING | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| WO-2023288242-A1 | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | disclosed |
| CN-109912683-B | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2023-01-06 | — | — | CN | disclosed |
| US-20230001001-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| CN-115505029-A | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-4100017-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PureTech LYT, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-4100005-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2022-12-14 | — | — | EP | disclosed |
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-12-13 | — | — | US | disclosed |
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| CN-115427044-A | Pyrrolopyrimidines as complement inhibitors | 拜奥克里斯特制药公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220378951-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| CN-115348864-A | Lipid prodrugs of neurosteroids | 纯技术LYT股份有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-115322208-A | Novel 2-aminothiazole derivatives, and preparation method and medical application thereof | 中国药科大学 | 2022-11-11 | — | — | CN | disclosed |
| US-11492345-B2 | Compounds and their methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220340581-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-10-27 | — | — | US | disclosed |
| US-20220323602-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-10-13 | — | — | US | disclosed |
| US-20220313837-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-10-06 | — | — | US | disclosed |
| US-20220313838-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-10-06 | — | — | US | disclosed |
| US-20220313836-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-10-06 | — | — | US | disclosed |
| EP-4065107-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2022-10-05 | — | — | EP | disclosed |
| CN-115151256-A | Novel compounds for the treatment of diseases associated with DUX expression | FACIO知识产权有限公司 | 2022-10-04 | — | — | CN | disclosed |
| US-11453666-B2 | Autotaxin inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-09-27 | — | — | US | disclosed |
| CN-115052596-A | ADAMTS inhibitor, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-115028551-A | Preparation method of azido-nonaethylene glycol-propionic acid | 成都普康生物科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-09-08 | — | — | US | disclosed |
| US-20220265595-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF INTREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LIMITED (GB) | 2022-08-25 | — | — | US | disclosed |
| US-20220249594-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2022-08-11 | — | — | US | disclosed |
| EP-4034535-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2022-08-03 | — | — | EP | disclosed |
| US-11400084-B2 | Aminoamide compounds | BIOTHERYX, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| CN-111518101-B | Pyrrolopyrimidine derivatives and uses thereof | 武汉人福创新药物研发中心有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-114746414-A | Aza-quinoline compounds and uses thereof | 诺华公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220213119-A1 | THIENOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CA LID (CN) | 2022-07-07 | — | — | US | disclosed |
| US-20220204512-A1 | SUBSTITUTED FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| WO-2022111700-A1 | PYRIDAZINONE DERIVATIVES AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2022-06-02 | — | — | WO | disclosed |
| EP-4003355-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-01 | — | — | EP | disclosed |
| CN-113651964-B | Lignin-based multifunctional composite flocculant and preparation method and application thereof | 华南理工大学 | 2022-05-24 | — | — | CN | disclosed |
| US-11339166-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2022-05-24 | — | — | US | disclosed |
| US-11325889-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2022-05-10 | — | — | US | disclosed |
| US-20220135589-A1 | TARGETED UBIQUITINATION DEGRADATION BRD4 PROTEIN COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-05-05 | — | — | US | disclosed |
| EP-3991752-A1 | CELL-BINDING MOLECULE-TUBULYSIN DERIVATIVE CONJUGATE AND PREPARATION METHOD THEREFOR | Hangzhou Dac Biotech Co., Ltd (CN) | 2022-05-04 | — | — | EP | disclosed |
| EP-3498717-B1 | COMPOSITION FOR HARDENING SOFT TISSUE | CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION (KR) | 2022-05-04 | — | — | EP | disclosed |
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| EP-3988599-A1 | THERMOPLASTIC RESIN, OPTICAL FILM MADE THEREFROM, DIOL COMPOUND, DIESTER COMPOUND | Mitsubishi Chemical Corporation (JP) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986476-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| US-20220106254-A1 | MIGRATION-RESISTANT PHOTOPOLYMERIZATION SENSITIZER | KAWASAKI KASEI CHEMICALS LTD. (JP) | 2022-04-07 | — | — | US | disclosed |
| EP-3978498-A1 | SUBSTITUTED FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINES | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2022-04-06 | — | — | EP | disclosed |
| US-20220081510-A1 | THERMOPLASTIC RESIN, OPTICAL FILM MADE THEREFROM, DIOL COMPOUND, DIESTER COMPOUND | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-17 | — | — | US | disclosed |
| CN-114173787-A | Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced diseases | 杨森科学爱尔兰无限公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3962602-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | Sitryx Therapeutics Limited (GB) | 2022-03-09 | — | — | EP | disclosed |
| EP-3962888-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | Sitryx Therapeutics Limited (GB) | 2022-03-09 | — | — | EP | disclosed |
| US-11267826-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20220064172-A1 | PYRROLOPYRIMIDINE DERIVATIVE AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2022-03-03 | — | — | US | disclosed |
| CN-114040778-A | Cell binding molecule-Tubulysin derivative conjugate and preparation method thereof | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-114040781-A | Formulation of conjugate of TUBULYSIN derivative and cell binding molecule | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-113950500-A | Thermoplastic resin, optical film comprising the same, diol compound, and diester compound | 三菱化学株式会社 | 2022-01-18 | — | — | CN | disclosed |
| EP-3930709-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | PureTech LYT, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3717471-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-01-05 | — | — | EP | disclosed |
| CN-109563055-B | Aminopyrazine compound or salt, isomer, preparation method and application thereof | 成都苑东生物制药股份有限公司 | 2021-12-24 | — | — | CN | disclosed |
| US-20210393790-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| CN-113825757-A | Substituted condensed bicyclic derivatives, preparation method and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-113825740-A | Itaconic acid derivatives and their use in the treatment of inflammatory diseases or diseases associated with adverse immune reactions | 西特瑞治疗有限公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3919498-A1 | PYRROLOPYRIMIDINE DERIVATIVE AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2021-12-08 | — | — | EP | disclosed |
| US-20210369855-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3331890-B1 | PROTECTED ORGANOBORONIC ACIDS WITH TUNABLE REACTIVITY, AND METHODS OF USE THEREOF | UNIV ILLINOIS (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11180471-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-23 | — | — | US | disclosed |
| US-20210353777-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
| CN-113651964-A | Lignin-based multifunctional composite flocculant and preparation method and application thereof | 华南理工大学 | 2021-11-16 | — | — | CN | disclosed |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210346523-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-11-11 | — | — | US | disclosed |
| CN-107531668-B | Therapeutic pyridazine compounds and uses thereof | 基因泰克公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113518779-A | Thienoheterocyclic derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2021-10-19 | — | — | CN | disclosed |
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-10-07 | — | — | US | disclosed |
| US-20210308277-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-10-07 | — | — | US | disclosed |
| WO-2021203025-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021202977-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3888691-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LIKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | Hangzhou Dac Biotech Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| CN-113473987-A | Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same | 细胞基因公司 | 2021-10-01 | — | — | CN | disclosed |
| US-11129910-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-09-28 | — | — | US | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
| CN-113292539-A | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-108026072-B | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2021159021-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158626-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3862023-A1 | CONJUGATES OF CELL-BINDING MOLECULES WITH CYTOTOXIC AGENTS | Hangzhou DAC Biotech Co, Ltd (CN) | 2021-08-11 | — | — | EP | disclosed |
| CN-113195487-A | 2, 3-diaminosuccinyl conjugate linkers | 杭州多禧生物科技有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113164775-A | Polycyclic compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides | 阿尔维纳斯运营股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166036-A | Photopolymerisable sensitizers having migration resistance | 川崎化成工业株式会社 | 2021-07-23 | — | — | CN | disclosed |
| EP-3846907-A1 | POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | Arvinas Operations, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| CN-107428752-B | Home chemokine inhibiting compounds | 癌症研究科技有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20210177794-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2021-06-17 | — | — | US | disclosed |
| CN-112824380-A | Alpha-fluoro chalcone derivative and application thereof | 杭州百诚医药科技股份有限公司 | 2021-05-21 | — | — | CN | disclosed |
| US-20210145812-A1 | AMINOAMIDE COMPOUNDS | BIOTHERYX, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| EP-3819305-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-05-12 | — | — | EP | disclosed |
| CN-108164513-B | Substituted oxopyridine derivatives and their use in the treatment of cardiovascular disorders | 拜耳制药股份公司 | 2021-05-07 | — | — | CN | disclosed |
| CN-109071697-B | Process for producing highly branched polymer and highly branched polymer | 国立大学法人京都大学 | 2021-04-23 | — | — | CN | disclosed |
| WO-2021063335-A1 | ERK1/2 PROTEIN KINASE INHIBITOR AND USE THEREOF | 南京药石科技股份有限公司 | 2021-04-08 | — | — | WO | disclosed |
| US-20210101903-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2021-04-08 | — | — | US | disclosed |
| WO-2021057853-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2021-04-01 | — | — | WO | disclosed |
| CN-112574207-A | ERK1/2 protein kinase inhibitor and application thereof | 南京药石科技股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-112543764-A | Amide compound with BET proteolysis induction effect and medical application thereof | 田边三菱制药株式会社 | 2021-03-23 | — | — | CN | disclosed |
| CN-108026014-B | Preparation method of optically active 2- (2-fluorobiphenyl-4-yl) propionic acid | 大正制药株式会社 | 2021-03-16 | — | — | CN | disclosed |
| US-10941117-B2 | 5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2021-03-09 | — | — | US | disclosed |
| EP-3453726-B1 | METHOD FOR PRODUCING MULTIBRANCHED POLYMER AND MULTIBRANCHED POLYMER | UNIV KYOTO (JP) | 2021-03-03 | — | — | EP | disclosed |
| US-20210052747-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| WO-2021018237-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-02-04 | — | — | WO | disclosed |
| WO-2021018118-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 PROTEINS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-04 | — | — | WO | disclosed |
| US-10905684-B2 | Aminoamide compounds | BIOTHERYX, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| WO-2021011720-A2 | ANTI-OSTEOARTHRITIS COMPOUNDS AND RELATED COMPOSITIONS AND METHODS | AVIDENCE THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20210009608-A1 | AZA-BENZOTHIOPHENE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-01-14 | — | — | US | disclosed |
| WO-2021000067-A1 | CELL-BINDING MOLECULE-TUBULYSIN DERIVATIVE CONJUGATE AND PREPARATION METHOD THEREFOR | 杭州多禧生物科技有限公司 | 2021-01-07 | — | — | WO | disclosed |
| EP-3468955-B1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3319956-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2021-01-06 | — | — | EP | disclosed |
| WO-2020258893-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2020-12-30 | — | — | WO | disclosed |
| EP-3344630-B1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-09 | — | — | EP | disclosed |
| US-10844081-B2 | Protected organoboronic acids with tunable reactivity, and methods of use thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-11-24 | — | — | US | disclosed |
| US-10829478-B2 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | GALAPAGOS NV (BE) | 2020-11-10 | — | — | US | disclosed |
| WO-2020213442-A1 | PHOTOPOLYMERIZABLE COMPOSITION, COATING FILM CONTAINING SAID PHOTOPOLYMERIZABLE COMPOSITION, AND CURING METHOD THEREFOR | 川崎化成工業株式会社 | 2020-10-22 | — | — | WO | disclosed |
| US-10808065-B2 | Method for producing multibranched polymer and multibranched polymer | KYOTO UNIVERSITY (JP) | 2020-10-20 | — | — | US | disclosed |
| WO-2020209209-A1 | RADICAL PHOTOCURING OXYGEN INHIBITION REDUCER, RADICAL PHOTOPOLYMERIZABLE COMPOSITION CONTAINING RADICAL PHOTOCURING OXYGEN INHIBITION REDUCER, COATING CONTAINING RADICAL PHOTOCURING OXYGEN INHIBITION REDUCER, AND METHOD FOR CURING SAME | 川崎化成工業株式会社 | 2020-10-15 | — | — | WO | disclosed |
| WO-2020208833-A1 | PHOTO-RADICALLY CURABLE OXYGEN-INHIBITION-REDUCING AGENT, PHOTO-RADICALLY CURABLE OXYGEN-INHIBITION-REDUCING AGENT-CONTAINING PHOTO-RADICALLY POLYMERIZABLE COMPOSITION, PHOTO-RADICALLY CURABLE OXYGEN-INHIBITION-REDUCING AGENT-CONTAINING COATING FILM, AND METHOD FOR CURING SAME | 川崎化成工業株式会社 | 2020-10-15 | — | — | WO | disclosed |
| EP-3717471-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | Galapagos NV (BE) | 2020-10-07 | — | — | EP | disclosed |
| WO-2020192750-A1 | THIENOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2020-10-01 | — | — | WO | disclosed |
| CN-111712240-A | Fatty acid derivatives for the treatment of non-alcoholic steatohepatitis | 巴斯夫股份公司 | 2020-09-25 | — | — | CN | disclosed |
| CN-109280174-B | Hyperbranched lignin grafted cationic polyacrylamide flocculant and preparation method thereof | 华南理工大学 | 2020-09-22 | — | — | CN | disclosed |
| CN-108026100-B | Substituted 1, 2-dihydro-3H-pyrrolo [1,2-c ] imidazol-3-one antibacterial agents | 爱杜西亚药品有限公司 | 2020-09-18 | — | — | CN | disclosed |
| EP-3302484-B1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200283435-A1 | Autotaxin Inhibitory Compunds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-09-10 | — | — | US | disclosed |
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| US-10758522-B2 | Small molecule analogs of the nemo binding peptide | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-09-01 | — | — | US | disclosed |
| CN-111518101-A | Pyrrolopyrimidine derivatives and uses thereof | 湖北生物医药产业技术研究院有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-20200247793-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2020156459-A1 | PYRROLOPYRIMIDINE DERIVATIVE AND USE THEREOF | 湖北生物医药产业技术研究院有限公司 | 2020-08-06 | — | — | WO | disclosed |
| CN-111433200-A | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2020-07-17 | — | — | CN | disclosed |
| US-20200215206-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SUZHOU M-CONJ BIOTECH CO., LTD. (CN) | 2020-07-09 | — | — | US | disclosed |
| US-20200216397-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2020-07-09 | — | — | US | disclosed |
| US-20200199074-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
| EP-3670514-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2020121544-A1 | MIGRATION-RESISTANT PHOTOPOLYMERIZATION SENSITIZER | 川崎化成工業株式会社 | 2020-06-18 | — | — | WO | disclosed |
| WO-2020121384-A1 | PHOTOPOLYMERIZATION SENSITIZER HAVING MIGRATION RESISTANCE | 川崎化成工業株式会社 | 2020-06-18 | — | — | WO | disclosed |
| EP-3468961-B1 | 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2020-06-10 | — | — | EP | disclosed |
| US-20200172480-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-06-04 | — | — | US | disclosed |
| CN-107880157-B | Preparation method and application of polyvinylpyrrolidone | 重庆斯泰克瑞登梅尔材料技术有限公司 | 2020-05-29 | — | — | CN | disclosed |
| US-10654846-B2 | Autotaxin inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| CN-107278203-B | 4, 6-substituted pyrazolo [1,5-a ] pyrazines as JANUS kinase inhibitors | 阵列生物制药公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-111093707-A | Tubulysin homolog conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
| EP-3630783-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20200102331-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-02 | — | — | US | disclosed |
| WO-2020054116-A1 | PHOTOPOLYMERIZATION SENSITIZER | 川崎化成工業株式会社 | 2020-03-19 | — | — | WO | disclosed |
| WO-2020054874-A1 | PHOTOPOLYMERIZATION SENSITIZER | 川崎化成工業株式会社 | 2020-03-19 | — | — | WO | disclosed |
| EP-3621652-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | Hangzhou DAC Biotech Co, Ltd (CN) | 2020-03-18 | — | — | EP | disclosed |
| EP-3099686-B1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-11 | — | — | EP | disclosed |
| US-20200069814-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-03-05 | — | — | US | disclosed |
| EP-3606922-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | Hangzhou Dac Biotech Co., Ltd (CN) | 2020-02-12 | — | — | EP | disclosed |
| US-10550100-B2 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | GALAPAGOS NV (BE) | 2020-02-04 | — | — | US | disclosed |
| WO-2020009176-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | 田辺三菱製薬株式会社 | 2020-01-09 | — | — | WO | disclosed |
| CN-110621673-A | Double-stranded linked cytotoxic drug conjugates | 杭州多禧生物科技有限公司 | 2019-12-27 | — | — | CN | disclosed |
| CN-107108579-B | Imidazolidine-2, 4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | 加拉帕戈斯股份有限公司 | 2019-12-17 | — | — | CN | disclosed |
| CN-110540521-A | Octahydro pentalene compound, preparation method and application thereof in medicine and pharmacology | BEIJING INNOCARE PHARMA TECH CO LTD | 2019-12-06 | — | — | CN | disclosed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | disclosed |
| US-20190315719-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-10-17 | — | — | US | disclosed |
| US-10441576-B2 | Substituted 1,2-dihydro-3H pyrrolo[1,2-c]imidazol-3 one antibacterials | IDORSIA PHARMACEUTICALS LTD. (CH) | 2019-10-15 | — | — | US | disclosed |
| WO-2019195063-A1 | AZA-BENZOTHIOPHENE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-10-10 | — | — | WO | disclosed |
| EP-3334737-B1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-10-09 | — | — | EP | disclosed |
| US-20190300503-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-10-03 | — | — | US | disclosed |
| US-10421742-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-24 | — | — | US | disclosed |
| EP-3538080-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LIKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | Hangzhou Dac Biotech Co. Ltd. (CN) | 2019-09-18 | — | — | EP | disclosed |
| EP-2687548-B1 | ORGANIC/INORGANIC COMPOSITE, MANUFACTURING METHOD THEREFOR, ORGANIC/INORGANIC COMPOSITE FILM, MANUFACTURING METHOD THEREFOR, PHOTONIC CRYSTAL, COATING MATERIAL, THERMOPLASTIC COMPOSITION, MICROSTRUCTURE, OPTICAL MATERIAL, ANTIREFLECTION MEMBER, AND OPTICAL LENS | ASAHI CHEMICAL IND (JP) | 2019-07-31 | — | — | EP | disclosed |
| US-10314823-B2 | Substituted 1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-11 | — | — | US | disclosed |
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| CN-105482199-B | Rubber composition and pneumatic tire | 住友橡胶工业株式会社 | 2019-05-28 | — | — | CN | disclosed |
| US-10294235-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2019-05-21 | — | — | US | disclosed |
| CN-109790179-A | Composition for hardening soft tissue | 加图立大学校产学协力团 | 2019-05-21 | — | — | CN | disclosed |
| EP-3468961-A1 | 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | Galapagos NV (BE) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468955-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | Galapagos NV (BE) | 2019-04-17 | — | — | EP | disclosed |
| US-20190106524-A1 | METHOD FOR PRODUCING MULTIBRANCHED POLYMER AND MULTIBRANCHED POLYMER | KYOTO UNIVERSITY (JP) | 2019-04-11 | — | — | US | disclosed |
| EP-3221300-B1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-03-20 | — | — | EP | disclosed |
| EP-3453726-A1 | METHOD FOR PRODUCING MULTIBRANCHED POLYMER AND MULTIBRANCHED POLYMER | Kyoto University (JP) | 2019-03-13 | — | — | EP | disclosed |
| WO-2019038362-A1 | ANTIBACTERIAL PYRROLOIMIDAZOLONES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-02-28 | — | — | WO | disclosed |
| US-10207976-B2 | Method for producing optically active 2-(2-fluorobiphenyl-4-yl) propanoic acid | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2019-02-19 | — | — | US | disclosed |
| EP-3237406-B1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-02-06 | — | — | EP | disclosed |
| US-20190031676-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-01-31 | — | — | US | disclosed |
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-22 | — | — | US | disclosed |
| US-10160762-B2 | 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-12-25 | — | — | US | disclosed |
| EP-3411074-A2 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | Suzhou M-conj Biotech Co., Ltd. (CN) | 2018-12-12 | — | — | EP | disclosed |
| US-10144732-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2018218154-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180339992-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RES INST (US) | 2018-11-29 | — | — | US | disclosed |
| US-10131730-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2018-11-20 | — | — | US | disclosed |
| EP-3114126-B1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-10-31 | — | — | EP | disclosed |
| EP-3389663-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | Southern Research Institute (US) | 2018-10-24 | — | — | EP | disclosed |
| US-10106544-B2 | 1,2-dihydro-3H-pyrrolo[1,2-C]imidazol-3-one derivatives and their use as antibacterial agents | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-10-23 | — | — | US | disclosed |
| WO-2018185526-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2018-10-11 | — | — | WO | disclosed |
| US-20180282252-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-(2-FLUOROBIPHENYL-4-YL) PROPANOIC ACID | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2018-10-04 | — | — | US | disclosed |
| US-20180258052-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2018-09-13 | — | — | US | disclosed |
| US-20180251434-A1 | ANTIBACTERIAL HETEROCYCLIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2018-09-06 | — | — | US | disclosed |
| US-20180250273-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-c]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | IDORSIA PHARMACEUTICALS LTD. (CH) | 2018-09-06 | — | — | US | disclosed |
| US-20180235938-A1 | SUBSTITUTED 1,2-DIHYDRO-3H PYRROLO[1,2-c]IMIDAZOL-3 ONE ANTIBACTERIALS | IDORSIA PHARMACEUTICALS LTD. (CH) | 2018-08-23 | — | — | US | disclosed |
| WO-2018148745-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES , INC. (US) | 2018-08-16 | — | — | WO | disclosed |
| EP-3357901-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-(2-FLUOROBIPHENYL-4-YL) PROPANOIC ACID | Taisho Pharmaceutical Co., Ltd. (JP) | 2018-08-08 | — | — | EP | disclosed |
| US-10023579-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023579-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023579-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
| EP-3344609-A1 | ANTIBACTERIAL HETEROCYCLIC DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2018-07-11 | — | — | EP | disclosed |
| EP-3143007-B1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-07-11 | — | — | EP | disclosed |
| EP-3344630-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | Idorsia Pharmaceuticals Ltd (CH) | 2018-07-11 | — | — | EP | disclosed |
| EP-3341378-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2018-07-04 | — | — | EP | disclosed |
| US-20180169078-A1 | Small Molecule Analogs of the Nemo Binding Peptide | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-06-21 | — | — | US | disclosed |
| EP-3334737-A1 | SUBSTITUTED 1,2-DIHYDRO-3H | Idorsia Pharmaceuticals Ltd (CH) | 2018-06-20 | — | — | EP | disclosed |
| EP-3333169-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-3331890-A1 | PROTECTED ORGANOBORONIC ACIDS WITH TUNABLE REACTIVITY, AND METHODS OF USE THEREOF | The Board of Trustees of the University of Illionis (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2018086139-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LIKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2018-05-17 | — | — | WO | disclosed |
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-17 | — | — | US | disclosed |
| EP-3319956-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-16 | — | — | EP | disclosed |
| US-20180110747-A1 | USE OF THIA OXO COMPOUNDS FOR LOWERING APO C3 | BASF AS (NO) | 2018-04-26 | — | — | US | disclosed |
| EP-3302484-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3302468-A1 | SMALL MOLECULE ANALOGS OF THE NEMO BINDING PEPTIDE | The Scripps Research Institute (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086742-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-9926281-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2018-03-27 | — | — | US | disclosed |
| WO-2018047983-A1 | INDANE DERIVATIVES USEFUL AS MODULATORS OF MGLUR7 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-15 | — | — | WO | disclosed |
| US-9908979-B2 | Polythiophene star copolymer capable of being self-doped by external stimulus, a method for producing the same, a conductive thin film using the same, and a method for producing the conductive thin film | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-03-06 | — | — | US | disclosed |
| US-20180036942-A1 | METHOD OF ADDITIVE MANUFACTURING USING PHOTOREGULATED RADICAL POLYMERIZATION | DOW GLOBAL TECHNOLOGIES LLC | 2018-02-08 | — | — | US | disclosed |
| WO-2018019296-A1 | AMINOPYRAZINE COMPOUND, SALT, OR ISOMER, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 成都苑东生物制药股份有限公司 | 2018-02-01 | — | — | WO | disclosed |
| US-20180016274-A1 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
| US-20180016274-A1 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
| EP-1600442-B1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | MSD KK (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-20180002293-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2018-01-04 | — | — | US | disclosed |
| EP-3262036-A1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| US-20170355687-A1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-12-14 | — | — | US | disclosed |
| WO-2017211666-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017211667-A1 | 5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2017-12-14 | — | — | WO | disclosed |
| US-9822102-B2 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-21 | — | — | US | disclosed |
| EP-3237406-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Galapagos NV (BE) | 2017-11-01 | — | — | EP | disclosed |
| US-9796686-B2 | Antibacterial quinazoline-4(3H)-one derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20170283424-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-9777001-B2 | Macrocycles with aromatic P2′ groups as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3221300-A1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2017-09-27 | — | — | EP | disclosed |
| CN-107108579-A | It is used for the derovatives of 5 [(base of piperazine 1) 3 oxopropyls] imidazolidine 2,4 for treating osteoarthritis as ADAMTS inhibitor | 加拉帕戈斯股份有限公司 | 2017-08-29 | — | — | CN | disclosed |
| US-20170240660-A1 | USING ORGANIC PHOTOREDOX CATALYSTS TO ACHIEVE METAL FREE PHOTOREGULATED CONTROLLED RADICAL POLYMERIZATION | DOW GLOBAL TECHNOLOGIES LLC | 2017-08-24 | — | — | US | disclosed |
| US-20170240660-A1 | USING ORGANIC PHOTOREDOX CATALYSTS TO ACHIEVE METAL FREE PHOTOREGULATED CONTROLLED RADICAL POLYMERIZATION | DOW GLOBAL TECHNOLOGIES LLC | 2017-08-24 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| WO-2017106771-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017106771-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174694-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-06-22 | — | — | US | disclosed |
| US-20170174694-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-06-22 | — | — | US | disclosed |
| US-20170174694-A1 | PYRROLOPYRIMIDINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-06-22 | — | — | US | disclosed |
| US-20170143841-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170143841-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | KODIAK SCIENCES INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170107223-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-20 | — | — | US | disclosed |
| EP-3152206-A1 | ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| US-20170096429-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-06 | — | — | US | disclosed |
| EP-3143007-A1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2017-03-22 | — | — | EP | disclosed |
| WO-2017037039-A1 | ANTIBACTERIAL HETEROCYCLIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017037221-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017036968-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | disclosed |
| EP-2993520-B1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHINETSU CHEMICAL CO (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-2993520-B1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHINETSU CHEMICAL CO (JP) | 2017-03-08 | — | — | EP | disclosed |
| WO-2017025562-A1 | SUBSTITUTED 1,2-DIHYDRO-3H PYRROLO[1,2-c]IMIDAZOL-3 ONE ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017027435-A1 | PROTECTED ORGANOBORONIC ACIDS WITH TUNABLE REACTIVITY, AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20170029535-A1 | REGULATION OF A CONTROLLED RADICAL POLYMERIZATION OF ACRYLATES BY LIGHT | DOW GLOBAL TECHNOLOGIES LLC | 2017-02-02 | — | — | US | disclosed |
| US-20170029535-A1 | REGULATION OF A CONTROLLED RADICAL POLYMERIZATION OF ACRYLATES BY LIGHT | DOW GLOBAL TECHNOLOGIES LLC | 2017-02-02 | — | — | US | disclosed |
| WO-2017005725-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-12 | — | — | WO | disclosed |
| US-20170007710-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2017-01-12 | — | — | US | disclosed |
| US-20170007710-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | KODIAK SCIENCES INC. | 2017-01-12 | — | — | US | disclosed |
| EP-3114126-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Actelion Pharmaceuticals Ltd (CH) | 2017-01-11 | — | — | EP | disclosed |
| US-20160368903-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | US | disclosed |
| WO-2016196071-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196071-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016191935-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196117-A1 | SMALL MOLECULE ANALOGS OF THE NEMO BINDING PEPTIDE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016191935-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
| EP-3099686-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160287715-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | KODIAK SCIENCES INC (US) | 2016-10-06 | — | — | US | disclosed |
| US-9458144-B2 | Monomer, polymer, resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9458144-B2 | Monomer, polymer, resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9458144-B2 | Monomer, polymer, resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9452972-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9434690-B2 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-06 | — | — | US | disclosed |
| WO-2016138114-A1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| CN-104379660-B | Rubber composition and pneumatic tire | 住友橡胶工业株式会社 | 2016-08-24 | — | — | CN | disclosed |
| WO-2016124939-A1 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016102347-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2016-06-30 | — | — | WO | disclosed |
| US-20160152755-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20160152755-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-06-02 | — | — | US | disclosed |
| WO-2016079688-A1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-05-26 | — | — | WO | disclosed |
| US-20160146974-A1 | REDOX PROCESSES FOR CONTACT LENS MODIFICATION | TELEFLEX LIFE SCIENCES LIMITED (MT) | 2016-05-26 | — | — | US | disclosed |
| EP-2590956-B1 | 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (S1P) receptors | MERCK SERONO SA (CH) | 2016-05-04 | — | — | EP | disclosed |
| EP-2993520-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | Shin-Etsu Chemical Co., Ltd. (JP) | 2016-03-09 | — | — | EP | disclosed |
| EP-2993520-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | Shin-Etsu Chemical Co., Ltd. (JP) | 2016-03-09 | — | — | EP | disclosed |
| US-20160052884-A1 | Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| EP-2539343-B1 | THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INTERNAT GMBH (DE) | 2015-12-30 | — | — | EP | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015173329-A1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-19 | — | — | WO | disclosed |
| US-20150322027-A1 | MONOMER, POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150322027-A1 | MONOMER, POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150322027-A1 | MONOMER, POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150313889-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2015-11-05 | — | — | US | disclosed |
| CN-102803238-B | Oxadiazole Derivatives | MERCK SERONO S.A. (CH) | 2015-09-30 | — | — | CN | disclosed |
| WO-2015132228-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-11 | — | — | WO | disclosed |
| US-9120119-B2 | Redox processes for contact lens modification | SEMPRUS BIOSCIENCES CORPORATION (US) | 2015-09-01 | — | — | US | disclosed |
| US-9115136-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-25 | — | — | US | disclosed |
| US-9115107-B2 | Heteroarylcarboxylic acid ester derivative | AJINOMOTO CO., INC. (JP) | 2015-08-25 | — | — | US | disclosed |
| WO-2015116885-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20150203639-A1 | POLYTHIOPHENE STAR COPOLYMER CAPABLE OF BEING SELF-DOPED BY EXTERNAL STIMULUS, A METHOD FOR PRODUCING THE SAME, A CONDUCTIVE THIN FILM USING THE SAME, AND A METHOD FOR PRODUCING THE CONDUCTIVE THIN FILM | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-07-23 | — | — | US | disclosed |
| US-20150197486-A9 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2015-07-16 | — | — | US | disclosed |
| US-9081283-B2 | Spatial and temporal control of brush formation on surfaces | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-14 | — | — | US | disclosed |
| US-9081283-B2 | Spatial and temporal control of brush formation on surfaces | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150152117-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-9029405-B2 | 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate(SIP)receptors | MERCK SERONO S.A. (CH) | 2015-05-12 | — | — | US | disclosed |
| EP-2188251-B1 | ARYLSULFONAMIDES WITH ANALGESIC ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2015-04-29 | — | — | EP | disclosed |
| EP-2188251-B1 | ARYLSULFONAMIDES WITH ANALGESIC ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2015-04-29 | — | — | EP | disclosed |
| US-9006359-B2 | Imbibing process for contact lens surface modification | SEMPRUS BIOSCIENCES CORPORATION (US) | 2015-04-14 | — | — | US | disclosed |
| US-9004682-B2 | Surface modified contact lenses | SEMPRUS BIOSCIENCES CORPORATION (US) | 2015-04-14 | — | — | US | disclosed |
| US-8999998-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000063-B2 | Multistep UV process to create surface modified contact lenses | SEMPRUS BIOSCIENCES CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| CN-104379660-A | Rubber composition and pneumatic tire | SUMITOMO RUBBER IND | 2015-02-25 | — | — | CN | disclosed |
| EP-2511271-B1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO KK (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-20150011511-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2015-01-08 | — | — | US | disclosed |
| US-20150004128-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | OLIGASIS, LLC (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150004128-A1 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES | OLIGASIS, LLC (US) | 2015-01-01 | — | — | US | disclosed |
| US-8921379-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-30 | — | — | US | disclosed |
| US-8916549-B2 | Thienooxazepine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| US-20140329818-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8877805-B2 | Heteroarylcarboxylic acid ester derivative | AJINOMOTO CO., INC. (JP) | 2014-11-04 | — | — | US | disclosed |
| US-8870372-B2 | Silicone hydrogel contact lens modified using lanthanide or transition metal oxidants | SEMPRUS BIOSCIENCES CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2791214-A1 | REDOX PROCESSES FOR CONTACT LENS MODIFICATION | Semprus Biosciences Corp. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2791212-A1 | HIGH IONIC STRENGTH PROCESS FOR CONTACT LENS MODIFICATION | Semprus Biosciences Corp. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2791211-A1 | MULTISTEP UV PROCESS TO CREATE SURFACE MODIFIED CONTACT LENSES | Semprus Biosciences Corp. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2791223-A1 | SURFACE MODIFIED CONTACT LENSES | Semprus Biosciences Corp. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2791215-A1 | IMBIBING PROCESS FOR CONTACT LENS SURFACE MODIFICATION | Semprus Biosciences Corp. (US) | 2014-10-22 | — | — | EP | disclosed |
| US-8853193-B2 | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-8846690-B2 | Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| EP-1725522-B1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8785443-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8778991-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140080790-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2014-03-20 | — | — | US | disclosed |
| US-8673948-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2463290-B1 | THIENOOXAZEPINE DERIVATIVE | TAKEDA PHARMACEUTICAL (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-8653260-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20140046056-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20140024776-A1 | HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS | OLIGASIS (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2079466-B1 | SUBSTITUTED INDOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8609715-B2 | Heteroarylcarboxylic acid ester derivative | AJINOMOTO CO., INC. (JP) | 2013-12-17 | — | — | US | disclosed |
| US-8592431-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8580816-B2 | Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring | SANOFI (FR) | 2013-11-12 | — | — | US | disclosed |
| EP-2061779-B1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INT (DE) | 2013-11-06 | — | — | EP | disclosed |
| EP-2523960-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI SA (FR) | 2013-10-16 | — | — | EP | disclosed |
| EP-2650279-A2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XenoPort, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20130245286-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245286-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245287-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245287-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| WO-2013115917-A1 | IMBIBING PROCESS FOR CONTACT LENS SURFACE MODIFICATION | SEMPRUS BIOSCIENCES CORP. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-8501786-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2384327-B1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-20130188124-A1 | HIGH IONIC STRENGTH PROCESS FOR CONTACT LENS MODIFICATION | SEMPRUS BIOSCIENCES CORP. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130176529-A1 | SILICONE HYDROGEL CONTACT LENS MODIFIED USING LANTHANIDE OR TRANSITION METAL OXIDANTS | SEMPRUS BIOSCIENCES CORP. (US) | 2013-07-11 | — | — | US | disclosed |
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-8481759-B2 | Process for producing wine lactone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| US-8481759-B2 | Process for producing wine lactone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| WO-2013090780-A1 | SURFACE MODIFIED CONTACT LENSES | SEMPRUS BIOSCIENCES CORP. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090808-A1 | HIGH IONIC STRENGTH PROCESS FOR CONTACT LENS MODIFICATION | SEMPRUS BIOSCIENCES CORP. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090813-A1 | REDOX PROCESSES FOR CONTACT LENS MODIFICATION | SEMPRUS BIOSCIENCES CORP. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090801-A1 | MULTISTEP UV PROCESS TO CREATE SURFACE MODIFIED CONTACT LENSES | SEMPRUS BIOSCIENCES CORP. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20130155371-A1 | REDOX PROCESSES FOR CONTACT LENS MODIFICATION | SEMPRUS BIOSCIENCES CORP. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| US-20130158211-A1 | IMBIBING PROCESS FOR CONTACT LENS SURFACE MODIFICATION | SEMPRUS BIOSCIENCES CORP. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130155370-A1 | SURFACE MODIFIED CONTACT LENSES | SEMPRUS BIOSCIENCES CORP. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158150-A1 | MULTISTEP UV PROCESS TO CREATE SURFACE MODIFIED CONTACT LENSES | SEMPRUS BIOSCIENCES CORP. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8450306-B2 | Bradykinin B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-8450306-B2 | Bradykinin B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-8450306-B2 | Bradykinin B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| EP-2590956-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTORS | Merck Serono S.A. (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20130116289-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE(SIP)RECEPTORS | MERCK SERONO S.A. (CH) | 2013-05-09 | — | — | US | disclosed |
| US-20130072502-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-03-21 | — | — | US | disclosed |
| US-8399480-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20130030193-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION | 2013-01-31 | — | — | US | disclosed |
| US-20130030193-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION | 2013-01-31 | — | — | US | disclosed |
| US-20130023557-A1 | CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[5,4-B]PYRIDINE RING | SANOFI (FR) | 2013-01-24 | — | — | US | disclosed |
| EP-2539343-A1 | THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| CN-102822154-A | Heteroarylcarboxylic acid ester derivative | AJINOMOTO KK | 2012-12-12 | — | — | CN | disclosed |
| EP-2523960-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| US-20120283222-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| EP-2274296-B1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2511271-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120258963-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2012-10-11 | — | — | US | disclosed |
| US-8283353-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-09 | — | — | US | disclosed |
| US-8252785-B2 | Aryl sulfonamides as bradykinin-B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| US-8252785-B2 | Aryl sulfonamides as bradykinin-B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| US-8252785-B2 | Aryl sulfonamides as bradykinin-B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| US-8247415-B2 | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-2485595-A1 | COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONIST AND AN ANTIMUSCARINIC AGENT | Merck Sharp & Dohme Corp. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2276756-B9 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120202819-A1 | COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONISTS AND AN ANTIMUSCARINIC AGENT | MERCK SHARP & DOHME CORPORATION (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120196848-A1 | THIENOOXAZEPINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| EP-2463290-A1 | THIENOOXAZEPINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-06-13 | — | — | EP | disclosed |
| WO-2012010862-A3 | IMPROVED COMBUSTIBLE COMPOSITION | RECKITT BENCKISER SOUTH AFRICA (PTY) LIMITED (ZA) | 2012-05-10 | — | — | WO | disclosed |
| EP-2448941-A2 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2443485-A2 | BIOMEDICAL DEVICES | Bausch & Lomb Incorporated (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2443110-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | Glaxo Group Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2012004287-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTORS | MERCK SERONO S.A. (CH) | 2012-01-12 | — | — | WO | disclosed |
| EP-2402329-A1 | Analgetic phenylsulphonamides | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-8083348-B2 | Biomedical devices | BAUSCH & LOMB INCORPORATED (US) | 2011-12-27 | — | — | US | disclosed |
| US-RE43038-E1 | Compound having antitumor activity and process for producing the same | RIKEN (JP) | 2011-12-20 | — | — | US | disclosed |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110294832-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-12-01 | — | — | US | disclosed |
| US-20110294775-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294775-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294775-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-2276756-B1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110288087-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-11-24 | — | — | US | disclosed |
| EP-2384327-A1 | FUSED RING COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-8026239-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-27 | — | — | US | disclosed |
| US-8026370-B2 | Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-27 | — | — | US | disclosed |
| US-8026262-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110212103-A1 | THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| WO-2011104340-A1 | THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011086080-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
| US-7964727-B2 | N-({1-[(cis-1,4-dihydroxycyclohexyl)methyl]piperidin-4-yl}methyl)-1-isopropyl-5-methyl-2-oxo-1, 2-dihydroquinoline-3-carboxamide ethanedioate; gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110144069-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2011-06-16 | — | — | US | disclosed |
| US-7943708-B2 | Method for the production of telechelic polymers | EVONIK RÖHM GMBH (DE) | 2011-05-17 | — | — | US | disclosed |
| WO-2011043942-A1 | COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONIST AND AN ANTIMUSCARINIC AGENT | MERCK SHARP & DOHME CORP. (US) | 2011-04-14 | — | — | WO | disclosed |
| EP-2284166-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2011-02-16 | — | — | EP | disclosed |
| EP-2284166-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2011-02-16 | — | — | EP | disclosed |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20110028481-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2011-02-03 | — | — | US | disclosed |
| US-20110021488-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021488-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021488-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2276756-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-2274296-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| WO-2011003065-A2 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-7858618-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-7858618-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-7858618-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| WO-2010146105-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010147876-A2 | BIOMEDICAL DEVICES | BAUSCH & LOMB INCORPORATED (US) | 2010-12-23 | — | — | WO | disclosed |
| EP-2264017-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
| US-20100317816-A1 | Biomedical devices | BAUSCH & LOMB INCORPORATED (US) | 2010-12-16 | — | — | US | disclosed |
| US-7834063-B2 | 4-[(Cyclopropylmethyl)(2-{[4-(1,1-dimethylethyl)phenyl]oxy}ethyl)amino]-2-(trifluoromethyl)benzonitrile; modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors; osteoporosis, muscle wasting,endometriosis, cardiovascular disease; breast, uterine cancer, prostatic hyperplasia | GLAXOSMITHKLINE LLC (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20100225013-A1 | METHOD FOR PRODUCING OPTICAL MEMBER AND OPTICAL MEMBER FORMED BY THE PRODUCTION PROCESS | FUJIFILM CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100197683-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-08-05 | — | — | US | disclosed |
| WO-2010087515-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | WO | disclosed |
| EP-2024355-B1 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7754743-B2 | Heteroarylcarbamoylbenzene derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-7745463-B2 | Alkene piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745463-B2 | Alkene piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745463-B2 | Alkene piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| EP-2188251-A1 | ARYLSULFONAMIDES WITH ANALGESIC ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | disclosed |
| EP-2188326-A2 | METHOD FOR PRODUCING OPTICAL MEMBER AND OPTICAL MEMBER FORMED BY THE PRODUCTION PROCESS | Fujifilm Corporation (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-7723385-B2 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| WO-2010056527-A2 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056527-A2 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| CN-1816550-B | Indolyl derivatives substituted with a thiazole ring and their use as PPAR modulators | HOFFMANN LA ROCHE | 2010-04-28 | — | — | CN | disclosed |
| US-7687525-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-30 | — | — | US | disclosed |
| CN-101679261-A | Piperazine and piperidine mglur5 potentiators | ASTRAZENECA AB | 2010-03-24 | — | — | CN | disclosed |
| EP-1689742-B1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7678869-B2 | Atom or group transfer radical polymerization | CARNEGIE MELLON UNIVERSITY (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678826-B2 | Organic compounds for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-03-16 | — | — | US | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100010178-A1 | METHOD FOR THE PRODUCTION OF TELECHELIC POLYMERS | EVONIK ROEHM GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| EP-1891029-B1 | ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS | NOVARTIS AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| EP-2134687-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | AstraZeneca AB (SE) | 2009-12-23 | — | — | EP | disclosed |
| EP-1238972-B1 | Novel carbazole derivative and chemically amplified radiation-sensitive resin composition | JSR CORP (JP) | 2009-12-16 | — | — | EP | disclosed |
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-7612213-B2 | (E)-ethyl 7-hydroxy-2-methyl-2-heptenate; (3E, 5E)-tert-butyl-9-(tert-butyldimethylsiloxy)-2-[(E)-ethylid ene]-4-methylnona-3,5-dienate | RIKEN (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
| WO-2009124166-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009123870-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090253741-A1 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253741-A1 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253741-A1 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2009-10-08 | — | — | US | disclosed |
| WO-2009124167-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-7572810-B2 | Alkene piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572810-B2 | Alkene piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572810-B2 | Alkene piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572820-B2 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| EP-2079466-A2 | SUBSTITUTED INDOLE COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090163588-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| EP-2061779-A1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | Boehringer Ingelheim International GmbH (DE) | 2009-05-27 | — | — | EP | disclosed |
| US-7528276-B2 | Process for preparing the intermediate compounds for PPAR α ligands | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2009-05-05 | — | — | US | disclosed |
| WO-2009055002-A1 | COMBINED INHIBITORS OF CYCLOOXYGENASE AND SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) (VASCULAR ADHESION PROTEIN, VAP-1) | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2009-04-30 | — | — | WO | disclosed |
| US-RE40703-E1 | Cell differentiation inducer, benzamide compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-04-28 | — | — | US | disclosed |
| US-20090105203-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| US-7521473-B2 | Inhibitors of protein tyrosine phosphatase 1B | WYETH (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521473-B2 | Inhibitors of protein tyrosine phosphatase 1B | WYETH (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521473-B2 | Inhibitors of protein tyrosine phosphatase 1B | WYETH (US) | 2009-04-21 | — | — | US | disclosed |
| US-7514470-B2 | Aniline derivatives as selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| WO-2009038222-A2 | METHOD FOR PRODUCING OPTICAL MEMBER AND OPTICAL MEMBER FORMED BY THE PRODUCTION PROCESS | FUJIFILM CORPORATION (JP) | 2009-03-26 | — | — | WO | disclosed |
| US-20090054435-A1 | Phenoxyalkanoic Acid Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| WO-2009021758-A1 | ARYLSULFONAMIDES HAVING AN ANALGESIC EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021758-A1 | ARYLSULFONAMIDES HAVING AN ANALGESIC EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021946-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021946-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2024355-A2 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | Bristol-Myers Squibb Company (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-2025675-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| EP-2025675-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2009017180-A1 | ORGANIC-INORGANIC HYBRID COMPOSITION AND ITS ARTICLE AND OPTICAL COMPONENT | FUJIFILM CORPORATION (JP) | 2009-02-05 | — | — | WO | disclosed |
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | MSD K.K. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20080269516-A1 | Process for Preparing the Intermediate Compounds for Pparalpha Ligands | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-10-30 | — | — | US | disclosed |
| US-7439266-B2 | Malononitrile compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-10-21 | — | — | US | disclosed |
| US-20080255124-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-10-16 | — | — | US | disclosed |
| US-7432287-B2 | Heteroarylcarbamoylbenzene derivative | BANYU PHARMECEUTICAL CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2008115281-A2 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080227774-A1 | 5,5-DISUBSTITUTED-INDOLIZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-18 | — | — | US | disclosed |
| US-20080227774-A1 | 5,5-DISUBSTITUTED-INDOLIZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-18 | — | — | US | disclosed |
| US-20080227774-A1 | 5,5-DISUBSTITUTED-INDOLIZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-18 | — | — | US | disclosed |
| WO-2008112440-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | WO | disclosed |
| US-20080207573-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1644368-B1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20080200466-A1 | Organic Compounds For the Treatment of Inflammatory or Allergic Conditions | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080194536-A1 | Cyanoarylamines | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080188489-A1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-08-07 | — | — | US | disclosed |
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | MITSUBISHI PHAMA CORPORATION (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1911738-A1 | PHENOXYALKANOIC ACID COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008042571-A2 | SUBSTITUTED INDOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008022945-A1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008022945-A1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7317028-B2 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-01-08 | — | — | US | disclosed |
| EP-1871379-A2 | CYANOARYLAMINES | Smithkline Beecham Corporation (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007146550-A2 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146550-A2 | ALKENE PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070287730-A1 | Alkene Piperidine Derivatives as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20070287730-A1 | Alkene Piperidine Derivatives as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20070287730-A1 | Alkene Piperidine Derivatives as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-7262211-B2 | Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation | DENDREON CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC | 2007-08-16 | — | — | US | disclosed |
| EP-1816128-A1 | CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-RE39754-E1 | Benzamide derivatives and pharmaceutical compositions containing same | SCHERING AG (DE) | 2007-07-31 | — | — | US | disclosed |
| EP-1809275-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7235572-B2 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| EP-1738752-A1 | Pharmaceutical combinations comprising cis-retine acid | Schering Aktiengesellschaft (DE) | 2007-01-03 | — | — | EP | disclosed |
| EP-1725522-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060258826-A1 | Atom or group transfer radical polymerization | CARNEGIE MELLON UNIVERSITY | 2006-11-16 | — | — | US | disclosed |
| EP-0966489-B1 | IMPROVEMENTS IN ATOM OR GROUP TRANSFER RADICAL POLYMERIZATION | UNIV CARNEGIE MELLON (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006113552-A2 | CYANOARYLAMINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
| US-7125938-B2 | Atom or group transfer radical polymerization | CARNEGIE MELLON UNIVERSITY (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1689742-A1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | Pfizer, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1572666-B1 | 3H-QUINAZOLIN-4-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-08-09 | — | — | EP | disclosed |
| CN-1816550-A | Indolyl derivatives substituted with a thiazole ring and their use as ppar modulators | HOFFMANN LA ROCHE (CH) | 2006-08-09 | — | — | CN | disclosed |
| US-7087612-B2 | Amine oxidase inhibitor; therapy for Alzheimer's diseases, Parkinson's disease | HOFFMANN-LA ROCHE INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | MSD K.K. (JP) | 2006-07-27 | — | — | US | disclosed |
| WO-2006044707-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1644368-A1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-12 | — | — | EP | disclosed |
| EP-1641458-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1615904-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2006-01-18 | — | — | EP | disclosed |
| US-20060004092-A1 | Malononitrile compound and use thereof pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| US-20050277645-A1 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-12-15 | — | — | US | disclosed |
| EP-1600442-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005097093-A1 | SLEEP INDUCING COMPOUNDS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-1373258-B1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PROD INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050209463-A1 | Novel compound having antitumor activity and process for producing the same | RIKEN (JP) | 2005-09-22 | — | — | US | disclosed |
| WO-2005085185-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050203087-A1 | Inhibitors of protein tyrosine phosphatase 1B | WYETH | 2005-09-15 | — | — | US | disclosed |
| EP-1572666-A1 | 3H-QUINAZOLIN-4-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005081954-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1487798-A4 | SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS | NEUROGEN CORP (US) | 2005-07-13 | — | — | EP | disclosed |
| US-6916830-B2 | Substituted tetrahydroisoquinolines as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
| WO-2005049608-A1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-06-02 | — | — | WO | disclosed |
| US-20050054647-A1 | New pharmaceutical combination | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20050049258-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| US-6846607-B2 | Carbazole derivative and chemically amplified radiation-sensitive resin composition | JSR CORPORATION (JP) | 2005-01-25 | — | — | US | disclosed |
| WO-2005005423-A1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-20 | — | — | WO | disclosed |
| US-20050004187-A1 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-01-06 | — | — | US | disclosed |
| EP-1487798-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6828333-B2 | Treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| EP-1480957-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004092135-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA (SE) | 2004-10-28 | — | — | WO | disclosed |
| US-20040204556-A1 | Atom or group transfer radical polymerization | MATYJASZEWSKI KRZYSZTOF (US) | 2004-10-14 | — | — | US | disclosed |
| US-20040204446-A1 | Nitrogen compounds such as N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl) -acetamide, administered for prophylaxis arthritis, psoriasis, cardiovascular disorders, reperfusion injury or respiratory system disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-10-14 | — | — | US | disclosed |
| US-6794392-B1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-6777422-B2 | FOR TREATING A VARIETY OF INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NEUROGEN CORP. | 2004-08-17 | — | — | US | disclosed |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | SCHERING AKTIENGESELLSCHAFT | 2004-07-29 | — | — | US | disclosed |
| US-20040142951-A1 | 3H-quinazolin-4-one derivatives as MAO-B inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | US | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| EP-1437346-A1 | Benzamide derivatives useful as cell differentiation inducers | Schering AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004054985-A1 | 3H-QUINAZOLIN-4-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-01 | — | — | WO | disclosed |
| EP-1244750-B1 | PIGMENT DISPERSIONS CONTAINING DISPERSANTS PREPARED BY CONTROLLED RADICAL POLYMERIZATION AND HAVING PENDANT HYDROPHILIC POLYMERIC SEGMENTS | PPG IND OHIO INC (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2004020399-A1 | MALONONITRILE COMPOUND AND USE THEREOF AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-03-11 | — | — | WO | disclosed |
| US-20040006069-A1 | Substituted tetrahydroisoquinolines as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-01-08 | — | — | US | disclosed |
| EP-1373258-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030236407-A1 | Perfluoroalkyl group-containing micelle-forming triiodoaromatic compounds, process for their production and their use as contrast media | SCHERING AG (DE) | 2003-12-25 | — | — | US | disclosed |
| US-6660734-B1 | Oxazinones having antibacterial activity | SIMON FRASER UNIVERSITY (CA) | 2003-12-09 | — | — | US | disclosed |
| US-20030207842-A1 | Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation | DENDREON PHARMACEUTICALS LLC | 2003-11-06 | — | — | US | disclosed |
| WO-2003082828-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003074495-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003048127-A1 | AROMATIC HETEROCYCLIC NON-COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION | CORVAS INTERNATIONAL, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| US-6576592-B1 | 2-(2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-(trifluoro-methyl) -1,2,3,6-tetrahydropyrimidin-1-yl)phenoxy)propionic acid ester and n-(phosphonomethyl)glycine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-06-10 | — | — | US | disclosed |
| EP-0858464-B1 | THROMBIN INHIBITORS | AKZO NOBEL NV (NL) | 2003-05-07 | — | — | EP | disclosed |
| US-6541580-B1 | Controlling living polymerization via e.g. polyphosphazene initiators | CARNEGIE MELLON UNIVERSITY | 2003-04-01 | — | — | US | disclosed |
| WO-2003020709-A1 | 1,2-OXAZIN-3-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS | SIMON FRASER UNIVERSITY (CA) | 2003-03-13 | — | — | WO | disclosed |
| US-20030027845-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2003-02-06 | — | — | US | disclosed |
| US-6512060-B1 | Contacting at least one first molecule comprising one or more radically transferable atoms or groups, and at least one second molecule comprising one or more radically transferable atoms or groups with a system comprising: a transition metal, | CARNEGIE MELLON UNIVERSITY | 2003-01-28 | — | — | US | disclosed |
| US-6498004-B1 | FRAGMENTABLE TWO-ELECTRON DONOR COMPOUNDS THAT ARE ATTACHED TO A PROTECTIVE GROUP WHEREIN SUCH PROTECTIVE GROUP IS ELIMINATED DURING DEVELOPMENT TO GIVE THE FRAGMENTABLE ELECTRON DONOR; WITHOUT AN INCREASE IN FOG | EASTMAN KODAK COMPANY | 2002-12-24 | — | — | US | disclosed |
| US-20020172885-A1 | Novel carbazole derivative and chemically amplified radiation-sensitive resin composition | JSR CORPORATION (JP) | 2002-11-21 | — | — | US | disclosed |
| US-20020142967-A1 | Thrombin inhibitors | ADANG A E P (NL) | 2002-10-03 | — | — | US | disclosed |
| EP-1244750-A1 | PIGMENT DISPERSIONS CONTAINING DISPERSANTS PREPARED BY CONTROLLED RADICAL POLYMERIZATION AND HAVING PENDANT HYDROPHILIC POLYMERIC SEGMENTS | PPG Industries Ohio, Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1238972-A1 | Novel carbazole derivative and chemically amplified radiation-sensitive resin composition | JSR Corporation (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-6441066-B1 | PIGMENT DISPERSANT PREPARED BY THE CONTROLLED RADICAL POLYMERIZATION OF A RADICALLY POLYMERIZABLE ETHYLENICALLY UNSATURATED FIRST MONOMER IN PRESENCE OF A POLYMERIC INITIATOR FORMS THE POLYMERIC BACBONE SEGMENT OF THE PIGMENT DISPERSANT | PPG INDUSTRIES OHIO, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6432921-B2 | OLIGOPEPTIDES | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| WO-2002060896-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| EP-1220024-A2 | Silver halide photographic element | EASTMAN KODAK COMPANY (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6399600-B1 | ANTIBIOTIC RESISTANT BATERIA INFECTIONS | SIMON FRASER UNIVERSITY (CA) | 2002-06-04 | — | — | US | disclosed |
| US-6372691-B2 | USING A PROPIONIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-04-16 | — | — | US | disclosed |
| EP-0966489-A4 | IMPROVEMENTS IN ATOM OR GROUP TRANSFER RADICAL POLYMERIZATION | UNIV CARNEGIE MELLON (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6294014-B1 | IN COATING FORMULATIONS USED AS CORROSION RESISTANCE PRIMERS IN AUTOMOTIVE TOPCOATS AND APPLIANCE INDUSTRIES | PPG INDUSTRIES OHIO, INC. | 2001-09-25 | — | — | US | disclosed |
| US-20010007764-A1 | THROMBIN INHIBITORS | N.V. ORGANON (NL) | 2001-07-12 | — | — | US | disclosed |
| WO-2001044376-A1 | PIGMENT DISPERSIONS CONTAINING DISPERSANTS PREPARED BY CONTROLLED RADICAL POLYMERIZATION AND HAVING PENDANT HYDROPHILIC POLYMERIC SEGMENTS | PPG INDUSTRIES OHIO, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| US-6174905-B1 | AS CARCINOSTATIC AGENT TO A HEMATOLOGIC MALIGNANCY AND A SOLID CARCINOMA | MITSUI CHEMICALS, INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| US-6080743-A | AS CHEMICAL INTERMEIDATES FOR PREPARING DRUGS | NOVARTIS AG (CH) | 2000-06-27 | — | — | US | disclosed |
| EP-0966489-A1 | IMPROVEMENTS IN ATOM OR GROUP TRANSFER RADICAL POLYMERIZATION | CARNEGIE MELLON UNIVERSITY (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998040415-A1 | IMPROVEMENTS IN ATOM OR GROUP TRANSFER RADICAL POLYMERIZATION | CARNEGIE MELLON UNIVERSITY (US) | 1998-09-17 | — | — | WO | disclosed |
| EP-0858464-A1 | THROMBIN INHIBITORS | Akzo Nobel N.V. (NL) | 1998-08-19 | — | — | EP | disclosed |
| EP-0853617-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | Novartis AG (CH) | 1998-07-22 | — | — | EP | disclosed |
| EP-0847992-A1 | Benzamide derivatives, useful as cell differentiation inducers | Mitsui Chemicals, Inc. (JP) | 1998-06-17 | — | — | EP | disclosed |
| US-5756812-A | Process for the preparation of pure (S,S)-N-(1-ethoxycarbonyl-3-phenylpropyl) alanine | DSM CHEMIE LINZ GMBH (AT) | 1998-05-26 | — | — | US | disclosed |
| WO-1997017363-A1 | THROMBIN INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-05-15 | — | — | WO | disclosed |
| WO-1997012884-A1 | HERBICIDAL 6-HETEROCYCLIC INDAZOLE DERIVATIVES | FMC CORPORATION (US) | 1997-04-10 | — | — | WO | disclosed |
| WO-1997008155-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| EP-0397511-B1 | Novel cephalosporin compounds and processes for preparation thereof | LUCKY LTD (KR) | 1996-09-04 | — | — | EP | disclosed |
| EP-0115770-B2 | Thiazole Derivatives | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-06-19 | — | — | EP | disclosed |
| WO-1993009101-A1 | MERCAPTO-AMIDE DERIVATIVES AS INHIBITORS OF THE NEUTRAL ENDOPEPTIDASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-13 | — | — | WO | disclosed |
| US-5202315-A | Antiboiotic | LUCKY, LTD. (KR) | 1993-04-13 | — | — | US | disclosed |
| WO-1992008721-A1 | NOVEL CEPHALOSPORIN COMPOUNDS AND PROCESSES FOR PREPARATION THEREOF | LUCKY, LTD. (KR) | 1992-05-29 | — | — | WO | disclosed |
| US-5095038-A | Antiinflammatory, antiallergens | ICI AMERICAS INC. (US) | 1992-03-10 | — | — | US | disclosed |
| US-5079369-A | N-acylating agent | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-01-07 | — | — | US | disclosed |
| US-5041460-A | Antiallergens, antiinflammatory agents and leukotriene antagonists | ICI AMERICAS INC. (US) | 1991-08-20 | — | — | US | disclosed |
| EP-0236307-B1 | ANTIHYPERTENSIVE AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF THE AGENTS AND COMPOSITIONS | SCHERING CORPORATION (US) | 1991-04-17 | — | — | EP | disclosed |
| US-4977179-A | Inhibiting angiotensin converting enzyme | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1990-12-11 | — | — | US | disclosed |
| EP-0397511-A2 | Novel cephalosporin compounds and processes for preparation thereof | LUCKY, LTD. (KR) | 1990-11-14 | — | — | EP | disclosed |
| US-4919708-A | Haloalkyl triazolinones and herbicidal use thereof | FMC CORPORATION (US) | 1990-04-24 | — | — | US | disclosed |
| US-4894386-A | ANTIINFLAMMATORY AGENTS | ICI AMERICAS INC. (US) | 1990-01-16 | — | — | US | disclosed |
| US-4886813-A | INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1989-12-12 | — | — | US | disclosed |
| US-4877873-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-10-31 | — | — | US | disclosed |
| US-4871860-A | Syn-isomer of 3,7-disubstituted-3-cephem-4-caroxylic acid compounds and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-10-03 | — | — | US | disclosed |
| US-4840772-A | KIT WITH CONTAINERS OF AGENT TO REDUCE INTRAOCULAR PRESSURE AND ANTIINFLAMMATORY STEROID OR BETA-BLOCKER | SCHERING CORPORATION (US) | 1989-06-20 | — | — | US | disclosed |
| US-4804752-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-02-14 | — | — | US | disclosed |
| US-4783444-A | SUBSTITUTED DIPEPTIDES | SCHERING CORPORATION (US) | 1988-11-08 | — | — | US | disclosed |
| US-4739066-A | HYPOTENSIVE AGENTS, ANGIOTENSIN INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-04-19 | — | — | US | disclosed |
| EP-0199794-A4 | HERBICIDAL ARYL TRIAZOLINONES. | FMC CORP (US) | 1987-09-28 | — | — | EP | disclosed |
| US-4695639-A | Thiazole derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-09-22 | — | — | US | disclosed |
| EP-0236307-A1 | ANTIHYPERTENSIVE AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF THE AGENTS AND COMPOSITIONS. | SCHERING CORP (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4691049-A | Process for preparing a specific diastereomer of a monoamino dicarboxylic acid ester | SCHERING CORPORATION (US) | 1987-09-01 | — | — | US | disclosed |
| EP-0115770-B1 | THIAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 1987-07-22 | — | — | EP | disclosed |
| EP-0221083-A1 | HALOALKYL TRIAZOLINONES | FMC Corporation (US) | 1987-05-13 | — | — | EP | disclosed |
| WO-1987001707-A1 | ANTIHYPERTENSIVE AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF THE AGENTS AND COMPOSITIONS | SCHERING CORPORATION (US) | 1987-03-26 | — | — | WO | disclosed |
| US-4642355-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1987-02-10 | — | — | US | disclosed |
| US-4638000-A | HYPOTENSIVES, ANGIOTENSIN INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-01-20 | — | — | US | disclosed |
| EP-0199794-A1 | HERBICIDAL ARYL TRIAZOLINONES | FMC Corporation (US) | 1986-11-05 | — | — | EP | disclosed |
| EP-0195817-A1 | CARBOXYALKYLDIPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | SCHERING CORP (US) | 1986-10-01 | — | — | EP | disclosed |
| WO-1986004481-A2 | HALOALKYL TRIAZOLINONES | FMC CORPORATION (US) | 1986-08-14 | — | — | WO | disclosed |
| US-4596791-A | Containing heterocyclic fused ring | USV PHARMACEUTICAL CORP. (US) | 1986-06-24 | — | — | US | disclosed |
| WO-1986002642-A1 | HERBICIDAL ARYL TRIAZOLINONES | FMC CORPORATION (US) | 1986-05-09 | — | — | WO | disclosed |
| US-4584285-A | Antihypertensive agents | SCHERING CORPORATION (US) | 1986-04-22 | — | — | US | disclosed |
| WO-1986001803-A1 | CARBOXYALKYLDIPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1986-03-27 | — | — | WO | disclosed |
| US-4575503-A | ANGIOTENSIN CONVERTING ENZYME INHIBITOR, HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1986-03-11 | — | — | US | disclosed |
| US-4564612-A | ANGIOTENSION CONVERTING ENZYME INHIBITORS, HYPOTENSIVE AGENTS, BENZOTHIAZEPINES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-01-14 | — | — | US | disclosed |
| EP-0156455-A2 | Condensed seven-membered ring compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-10-02 | — | — | EP | disclosed |
| US-4544653-A | BACTERICIDAL CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-10-01 | — | — | US | disclosed |
| EP-0040793-B1 | NOVEL QUINAZOLINE-DIONE COMPOUNDS, PROCESS FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | Ishikawa, Masayuki (JP) | 1985-08-28 | — | — | EP | disclosed |
| US-4493833-A | BACTERICIDES, ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-01-15 | — | — | US | disclosed |
| EP-0125056-A2 | Condensed, seven-membered ring compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1984-11-14 | — | — | EP | disclosed |
| EP-0121830-A2 | Substituted dipeptides as antihypertensives | USV PHARMACEUTICAL CORPORATION (US) | 1984-10-17 | — | — | EP | disclosed |
| US-4474779-A | ANTIBIOTICS, BACTERICIDES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1984-10-02 | — | — | US | disclosed |
| US-4473575-A | ANGIOTENSIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1984-09-25 | — | — | US | disclosed |
| US-4468396-A | DIURETICS | SCHERING CORPORATION (US) | 1984-08-28 | — | — | US | disclosed |
| EP-0115770-A1 | Thiazole Derivatives | Takeda Chemical Industries, Ltd. (JP) | 1984-08-15 | — | — | EP | disclosed |
| US-4431643-A | CEPHALOSPORINS; BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-02-14 | — | — | US | disclosed |
| US-4410520-A | ANGIOTENSION CONVERTING ENZYME INGIBITOR, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
| US-4405623-A | HYPOTENSIVE AGENTS, VASODILATORS | MASAYUKI ISHIKAWA (JP) | 1983-09-20 | — | — | US | disclosed |
| US-4364943-A | CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-12-21 | — | — | US | disclosed |
| US-4331664-A | BACTERIOSTATS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-05-25 | — | — | US | disclosed |
| EP-0048159-A2 | Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents | UNIVERSITY OF MIAMI (US) | 1982-03-24 | — | — | EP | disclosed |
| US-4316019-A | AMIDATION BY A 2-ALKOXYIMINO-2-THIAZOLYLACETIC ACID | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-02-16 | — | — | US | disclosed |
| US-4304770-A | Syn-isomer of 3,7-disubstituted-3-cephem-4-carboxylic acid compounds and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-08 | — | — | US | disclosed |
| EP-0040793-A1 | Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof | Ishikawa, Masayuki (JP) | 1981-12-02 | — | — | EP | disclosed |
| US-4279818-A | CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-07-21 | — | — | US | disclosed |
| US-4166115-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-08-28 | — | — | US | disclosed |
| US-3975432-A | Process for preparing 2-(6-methoxy-2-naphthyl)propionic acid | SYNTEX CORPORATION (PM) | 1976-08-17 | — | — | US | disclosed |
| US-3975432-A | Process for preparing 2-(6-methoxy-2-naphthyl)propionic acid | SYNTEX CORPORATION (PM) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207842-A1 | Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation | PLAT, PLAU, SERPINE1 | CA12 3748/4885CA14 2702/4885DGAT1 2639/4885 |
| US-20090137545-A1 | Compounds | ADORA2B, ABCB11, CYP11B1 | CA12 1132/4885CA14 1479/4885DGAT1 3138/4885 |
| US-20210177794-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | CPT1A, NR1H3, NR1H2 | CA12 3745/4885CA14 4173/4885DGAT1 61/4885 |
| US-20210052747-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SLC25A1, GCDH, FH | CA12 31/4885CA14 40/4885DGAT1 2128/4885 |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | CA12 937/4885CA14 765/4885DGAT1 767/4885 |
| US-20180282252-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-(2-FLUOROBIPHENYL-4-YL) PROPANOIC ACID | ME1, PKD1, CA2 | CA12 476/4885CA14 638/4885DGAT1 1362/4885 |
| US-20050277645-A1 | Sleep inducing compounds and methods relating thereto | CNR1, CNR2, MTNR1B | CA12 3274/4885CA14 3064/4885DGAT1 4049/4885 |
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | CA12 1162/4885CA14 913/4885DGAT1 803/4885 |
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | HTR4, HRH4, HRH2 | CA12 4751/4885CA14 4336/4885DGAT1 3075/4885 |
| US-20200247793-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CA12 1391/4885CA14 2299/4885DGAT1 458/4885 |
| US-10160762-B2 | 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors | PDE12, PDE2A, PDE4D | CA12 3870/4885CA14 4573/4885DGAT1 1055/4885 |
| US-20230165930-A1 | CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | TEKT1, CD2BP2, TEK | CA12 1484/4885CA14 600/4885DGAT1 4412/4885 |
| US-20240245788-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | CA12 937/4885CA14 765/4885DGAT1 767/4885 |
| US-20230277616-A9 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | PHOSPHO1, MSN, ZW10 | CA12 189/4885CA14 148/4885DGAT1 1681/4885 |
| US-20160287715-A1 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES | PHOSPHO1, MSN, ZW10 | CA12 189/4885CA14 148/4885DGAT1 1681/4885 |
| US-11773109-B2 | Composition for hardening soft tissue | PNLIP, AMY2A, RNASE1 | CA12 2826/4885CA14 2410/4885DGAT1 1150/4885 |
| US-20140080790-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | DPP4, DPP9, DPP7 | CA12 2332/4885CA14 1173/4885DGAT1 1028/4885 |
| US-20130116289-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE(SIP)RECEPTORS | S1PR1, S1PR5, S1PR2 | CA12 4870/4885CA14 4795/4885DGAT1 2244/4885 |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | CA12 1323/4885CA14 1151/4885DGAT1 1854/4885 |
| US-10294235-B2 | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof | LRRK2, PRKDC, DAPK2 | CA12 4878/4885CA14 4882/4885DGAT1 4341/4885 |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CA12 1391/4885CA14 2299/4885DGAT1 458/4885 |
| US-20220081510-A1 | THERMOPLASTIC RESIN, OPTICAL FILM MADE THEREFROM, DIOL COMPOUND, DIESTER COMPOUND | RTF1, RNF10, RAD51 | CA12 3307/4885CA14 4337/4885DGAT1 845/4885 |
| US-20140046056-A1 | FUSED RING COMPOUND AND USE THEREOF | PPARA, PPARG, AGTR2 | CA12 4762/4885CA14 4785/4885DGAT1 947/4885 |
| US-11267826-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | CA12 3028/4885CA14 3036/4885DGAT1 2899/4885 |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | CA12 909/4885CA14 916/4885DGAT1 597/4885 |
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | CA12 3217/4885CA14 2928/4885DGAT1 619/4885 |
| US-12508321-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD4, CD2, B2M | CA12 342/4885CA14 253/4885DGAT1 1089/4885 |
| US-20200069814-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | CA12 716/4885CA14 638/4885DGAT1 3716/4885 |
| US-20110028481-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CA12 4881/4885CA14 4883/4885DGAT1 4171/4885 |
| US-11492345-B2 | Compounds and their methods of use | SCN1A, SCN3A, SCN1B | CA12 1391/4885CA14 2299/4885DGAT1 458/4885 |
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | CA12 4025/4885CA14 4296/4885DGAT1 3757/4885 |
| US-20120190665-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | CA12 4025/4885CA14 4296/4885DGAT1 3757/4885 |
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | PPARA, PPARD, PPARG | CA12 2876/4885CA14 3028/4885DGAT1 188/4885 |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | GRM5, GRM1, GRM2 | CA12 4789/4885CA14 4877/4885DGAT1 2766/4885 |
| US-20200216397-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | ADAMTS1, ADAMTS5, ADAMTS7 | CA12 3903/4885CA14 3920/4885DGAT1 4037/4885 |
| US-20240391875-A1 | ISOQUINOLINONES AND QUINOLINONES AS MODULATORS OF POLRMT | POLRMT, TFAM, POLM | CA12 4863/4885CA14 4867/4885DGAT1 428/4885 |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | CA12 1201/4885CA14 1013/4885DGAT1 1857/4885 |
| US-20220265595-A1 | ITACONIC ACID DERIVATIVES AND USES THEREOF INTREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | IL1R1, IL1B, IL1A | CA12 2391/4885CA14 2577/4885DGAT1 391/4885 |
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | STAT6, STAT3, STAT1 | CA12 2563/4885CA14 2021/4885DGAT1 410/4885 |
| US-20150197486-A9 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | CA12 1201/4885CA14 1013/4885DGAT1 1857/4885 |
| US-20190315719-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | ADAMTS5, ADAMTS4, ADAMTS1 | CA12 4481/4885CA14 4024/4885DGAT1 4392/4885 |
| US-20230165931-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | TEKT1, CD2BP2, CD4 | CA12 1484/4885CA14 606/4885DGAT1 4378/4885 |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | CA12 3668/4885CA14 3747/4885DGAT1 3792/4885 |
| US-20120283222-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | DPP4, DPP9, DPP7 | CA12 2332/4885CA14 1173/4885DGAT1 1028/4885 |
| US-20120258963-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CA12 4881/4885CA14 4883/4885DGAT1 4171/4885 |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | C5, C9, C1QBP | CA12 4654/4885CA14 4449/4885DGAT1 4586/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | CA12 4707/4885CA14 4664/4885DGAT1 345/4885 |
| US-20050203087-A1 | Inhibitors of protein tyrosine phosphatase 1B | PTPRO, PTPRS, PTPRM | CA12 4598/4885CA14 4308/4885DGAT1 2252/4885 |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CA12 4881/4885CA14 4883/4885DGAT1 4171/4885 |
| US-20110021488-A1 | New Compounds | ABCG2, ADORA2B, ADORA3 | CA12 1433/4885CA14 1771/4885DGAT1 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.